Bladder cancer patients who run out of options often face a grim choice: life-altering surgery to remove the bladder, or living with a disease that might kill them if it spreads to the rest of the ...

PD-1 inhibitors are projected to dominate future drug sales. Immuno-oncology therapies, particularly the PD-(L)1 class, have revolutionized cancer ca ...

Roche has found redemption in a precision medicine approach following an earlier Tecentriq trial flop in a broader bladder ...

Natera (NTRA) announced positive topline results from the randomized, phase III IMvigor011 clinical trial in muscle-invasive bladder cancer. The ...